Scopus Biopharma Inc Stock
Scopus Biopharma Inc Stock price
Key metrics
| Market capitalization | $10.00k |
| Enterprise Value | $-1.40m |
| EV/FCF (TTM) EV/FCF | 0.46 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-9.34m |
| Free Cash Flow (TTM) Free Cash Flow | $-3.04m |
| Cash position | $360.00k |
| EPS (TTM) EPS | $-0.32 |
| Short interest | 0.25% |
Is Scopus Biopharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
Scopus Biopharma Inc Stock Analysis
Analyst Opinions
1 Analyst has issued a forecast Scopus Biopharma Inc:
Analyst Opinions
1 Analyst has issued a forecast Scopus Biopharma Inc:
Financial data from Scopus Biopharma Inc
| Jun '23 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -9.34 -9.34 |
46%
46%
|
EBIT (Operating Income) EBIT | -9.34 -9.34 |
46%
46%
|
| Net Profit | -8.70 -8.70 |
45%
45%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Scopus Biopharma Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Scopus Biopharma, Inc. is a biopharmaceutical company, which engages in the development of transformational therapeutics targeting serious diseases with unmet medical needs. Its drug candidates comprises of combination of cannabidiol-mediated, opioid-sparing anesthetics, synthesis of cannabinoids, and cannabinoid receptor mediating compounds for the treatment of systemic sclerosis. The company was founded on April 18, 2017 and is headquartered in New York, NY.
| Head office | United States |
| CEO | Morris Laster |
| Founded | 2017 |
| Website | www.scopusbiopharma.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
